By contrast, increasingly activated CD8+ tumor-infiltrating lymphocytes (TIL) were observed in the TME after treatment with the iADC (as assessed by CD69, 1,219.75 ± 25.46 gMFI in anti–PD-1 plus mTAK-500–treated animals vs. 1,053.80 ± 58.06 gMFI in mTAK-500–treated animals; Fig. 5B), supporting that the combination of anti–PD-1 with mTAK-500 led to increased efficacy mediated, at least in part, to enhanced T cell–mediated tumor elimination. This evidence concerns the gene CD69 and neoplasm.